[go: up one dir, main page]

NO20025154D0 - Imidazopyrimidinderivater og triazolpyrimidinderivater - Google Patents

Imidazopyrimidinderivater og triazolpyrimidinderivater

Info

Publication number
NO20025154D0
NO20025154D0 NO20025154A NO20025154A NO20025154D0 NO 20025154 D0 NO20025154 D0 NO 20025154D0 NO 20025154 A NO20025154 A NO 20025154A NO 20025154 A NO20025154 A NO 20025154A NO 20025154 D0 NO20025154 D0 NO 20025154D0
Authority
NO
Norway
Prior art keywords
sup
sub
derivatives
optionally substituted
imidazopyrimidine
Prior art date
Application number
NO20025154A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025154L (no
Inventor
Takeshi Yura
Arnel B Concepcion
Gyoonhee Han
Makiko Marumo
Hiroko Katsumata
Norihiro Kawamura
Toshio Kokubo
Hiroshi Komura
Yingfu Li
Timothy Bruno Lowinger
Muneto Mogi
Noriyuki Yamamoto
Nagahiro Yoshida
Scott C Miller
Margaret A Popp
Niko M Redmann
Martha E Rodriguez
William J Scott
Ming Wang
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO20025154L publication Critical patent/NO20025154L/no
Publication of NO20025154D0 publication Critical patent/NO20025154D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20025154A 2000-04-28 2002-10-25 Imidazopyrimidinderivater og triazolpyrimidinderivater NO20025154D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000128870A JP2001302667A (ja) 2000-04-28 2000-04-28 イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
PCT/EP2001/004357 WO2001083485A1 (en) 2000-04-28 2001-04-17 Imidazopyrimidine derivatives and triazolopyrimidine derivatives

Publications (2)

Publication Number Publication Date
NO20025154L NO20025154L (no) 2002-10-25
NO20025154D0 true NO20025154D0 (no) 2002-10-25

Family

ID=18638240

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025154A NO20025154D0 (no) 2000-04-28 2002-10-25 Imidazopyrimidinderivater og triazolpyrimidinderivater

Country Status (37)

Country Link
US (1) US6911443B2 (xx)
EP (1) EP1278750B1 (xx)
JP (2) JP2001302667A (xx)
KR (1) KR20030009456A (xx)
CN (1) CN1263756C (xx)
AR (1) AR033367A1 (xx)
AT (1) ATE272639T1 (xx)
AU (1) AU783043B2 (xx)
BG (1) BG107166A (xx)
BR (1) BR0110404A (xx)
CA (1) CA2407531A1 (xx)
CZ (1) CZ20023551A3 (xx)
DE (1) DE60104671T2 (xx)
DK (1) DK1278750T3 (xx)
DO (1) DOP2001000151A (xx)
EE (1) EE200200606A (xx)
ES (1) ES2225546T3 (xx)
HR (1) HRP20020943A2 (xx)
HU (1) HUP0300846A2 (xx)
IL (1) IL151919A0 (xx)
MA (1) MA25746A1 (xx)
MX (1) MXPA02010579A (xx)
MY (1) MY141578A (xx)
NO (1) NO20025154D0 (xx)
NZ (2) NZ522241A (xx)
PE (1) PE20011287A1 (xx)
PL (1) PL358106A1 (xx)
PT (1) PT1278750E (xx)
RU (1) RU2306313C2 (xx)
SI (1) SI1278750T1 (xx)
SK (1) SK15332002A3 (xx)
SV (1) SV2001000416A (xx)
TR (1) TR200402300T4 (xx)
TW (1) TWI222974B (xx)
UA (1) UA72615C2 (xx)
WO (1) WO2001083485A1 (xx)
ZA (1) ZA200207676B (xx)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60216747T2 (de) 2001-04-09 2007-10-04 Novartis Vaccines and Diagnostics, Inc., Emeryville Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
US20070129383A1 (en) * 2003-10-17 2007-06-07 Hiroshi Kuramochi Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
PL1718649T3 (pl) * 2004-01-31 2009-11-30 Actimis Pharmaceuticals Inc Pochodne kwasu imidazo[1,2-c]pirymidynylooctowego
AU2005260031B2 (en) * 2004-06-25 2008-10-09 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
BRPI0514544A (pt) 2004-08-23 2008-06-17 Wyeth Corp ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1)
US7186749B2 (en) 2004-08-23 2007-03-06 Wyeth Pyrrolo-naphthyl acids and methods for using them
CN101044127A (zh) 2004-08-23 2007-09-26 惠氏公司 用作纤溶酶原激活剂抑制剂－1的噻唑基－萘基酸
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
WO2006093247A1 (ja) 2005-02-28 2006-09-08 Japan Tobacco Inc. Ｓｙｋ阻害活性を有する新規なアミノピリジン化合物
US7442700B2 (en) 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009511528A (ja) * 2005-10-13 2009-03-19 グラクソ グループ リミテッド Ｓｙｋ阻害物質としてのピロロピリミジン誘導体群
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN103288833B (zh) * 2006-11-22 2018-01-12 因塞特控股公司 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶
US20100298557A1 (en) 2006-12-28 2010-11-25 Taisho Pharmaceutical Co., Ltd Pyrazolopyrimidine compound
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
RU2491279C2 (ru) 2007-09-25 2013-08-27 Актимис Фармасьютикалз, Инк. 2-s-бензилзамещенные пиримидины в качестве антагонистов crth2
TW200922587A (en) 2007-09-25 2009-06-01 Actimis Pharmaceuticals Inc Alkylthio pyrimidines as CRTH2 antagonists
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
SG171993A1 (en) 2008-12-08 2011-07-28 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
JP5567587B2 (ja) 2008-12-08 2014-08-06 ギリアード コネチカット， インコーポレイテッド イミダゾピラジンＳｙｋ阻害剤
JP5744859B2 (ja) * 2009-06-15 2015-07-08 ライジェル ファーマシューティカルズ， インコーポレイテッド 脾臓チロシンキナーゼ（ｓｙｋ）の小分子阻害薬
US8440689B2 (en) 2009-12-23 2013-05-14 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones
US9562056B2 (en) 2010-03-11 2017-02-07 Gilead Connecticut, Inc. Imidazopyridines Syk inhibitors
CN102985424B (zh) * 2010-04-14 2015-03-11 阵列生物制药公司 5,7-取代的-咪唑并[1,2-c]嘧啶
WO2012154518A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
KR20140028062A (ko) 2011-05-10 2014-03-07 머크 샤프 앤드 돔 코포레이션 Syk 억제제로서의 아미노피리미딘
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
WO2013052391A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2013052394A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
WO2013052393A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
CN103987713A (zh) * 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
KR101744607B1 (ko) * 2011-12-28 2017-06-08 후지필름 가부시키가이샤 신규인 니코틴아미드 유도체 또는 그 염
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
EP2863914B1 (en) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
US9416111B2 (en) 2012-06-22 2016-08-16 Merck Sharp & Dohme Corp. Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
WO2013192098A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
EP2934525B1 (en) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9499534B2 (en) 2013-04-26 2016-11-22 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
EP2988744A4 (en) 2013-04-26 2016-11-02 Merck Sharp & Dohme THIAZOLSUBSTITUTED AMINOHETEROARYLE AS MILZTYROSINKINASE INHIBITOR
SI3027618T1 (sl) 2013-07-30 2021-01-29 Kronos Bio, Inc. Polimorf SYK inhibitorjev
HK1222329A1 (zh) 2013-07-30 2017-06-30 吉利德康涅狄格公司 Syk抑制劑的製劑
EA201690608A1 (ru) 2013-12-04 2016-12-30 Джилид Сайэнс, Инк. Способы лечения раковых заболеваний
WO2015095445A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3082807B1 (en) 2013-12-20 2018-07-04 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
ME03472B (me) 2014-03-19 2020-01-20 Boehringer Ingelheim Int Heteroarilni sik inhibitori
JP6310144B2 (ja) 2014-07-14 2018-04-18 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための組み合わせ
MX2018003008A (es) 2015-09-11 2018-04-11 Boehringer Ingelheim Int Heteroarilos sustituidos con pirazolilo y su uso como medicamentos.
AU2018321264A1 (en) 2017-08-25 2020-02-27 Kronos Bio, Inc. Polymorphs of Syk inhibitors
CN111194319A (zh) 2017-10-19 2020-05-22 拜耳动物保健有限责任公司 稠合的杂芳族吡咯烷酮类化合物用于治疗和预防动物中的疾病的用途
JP7382316B2 (ja) * 2017-11-14 2023-11-16 ザ チルドレンズ メディカル センター コーポレーション ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
KR102740831B1 (ko) 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
WO2019235572A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 固形がんの処置剤および医薬組成物
US20210113540A1 (en) * 2018-06-06 2021-04-22 National University Corporation Hokkaido University Treatment agent and pharmaceutical composition for glioma
WO2019235571A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 血液がんの処置剤および医薬組成物
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer
JP2023549360A (ja) * 2020-11-13 2023-11-24 バイオジェン・エムエイ・インコーポレイテッド Ｂｔｋ阻害剤としてのピラゾロ［１，５－ａ］ピラジン誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483987A (en) * 1983-06-20 1984-11-20 G. D. Searle & Co. 8-Substituted 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines and amides
FR2549834B1 (fr) * 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
EP1017682A4 (en) * 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
ATE401312T1 (de) * 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
US6673564B2 (en) * 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
HUP0300846A2 (hu) 2003-08-28
TWI222974B (en) 2004-11-01
NZ526221A (en) 2005-01-28
IL151919A0 (en) 2003-04-10
SI1278750T1 (en) 2005-02-28
RU2306313C2 (ru) 2007-09-20
NO20025154L (no) 2002-10-25
EE200200606A (et) 2004-04-15
BR0110404A (pt) 2003-02-11
HK1058362A1 (en) 2004-05-14
EP1278750B1 (en) 2004-08-04
PT1278750E (pt) 2004-11-30
JP2003535067A (ja) 2003-11-25
US6911443B2 (en) 2005-06-28
AU6220401A (en) 2001-11-12
PL358106A1 (en) 2004-08-09
CZ20023551A3 (cs) 2003-01-15
MY141578A (en) 2010-05-14
DK1278750T3 (da) 2004-11-22
ES2225546T3 (es) 2005-03-16
NZ522241A (en) 2004-04-30
CN1439009A (zh) 2003-08-27
AR033367A1 (es) 2003-12-17
BG107166A (bg) 2003-06-30
MA25746A1 (fr) 2003-04-01
WO2001083485A1 (en) 2001-11-08
SV2001000416A (es) 2001-07-03
CA2407531A1 (en) 2001-10-25
PE20011287A1 (es) 2002-02-27
MXPA02010579A (es) 2003-05-14
JP2001302667A (ja) 2001-10-31
CN1263756C (zh) 2006-07-12
HRP20020943A2 (en) 2005-02-28
SK15332002A3 (sk) 2003-06-03
TR200402300T4 (tr) 2004-12-21
ZA200207676B (en) 2003-09-25
AU783043B2 (en) 2005-09-22
DE60104671T2 (de) 2005-12-29
KR20030009456A (ko) 2003-01-29
UA72615C2 (en) 2005-03-15
DOP2001000151A (es) 2002-05-15
DE60104671D1 (de) 2004-09-09
US20040054179A1 (en) 2004-03-18
ATE272639T1 (de) 2004-08-15
EP1278750A1 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
NO20025154D0 (no) Imidazopyrimidinderivater og triazolpyrimidinderivater
FI970317A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
EA200000334A1 (ru) Производные карбоксамидотиазолов, их получение, содержащие их фармацевтические композиции
NO2015020I2 (no) Ceritinib eller et farmasøytisk akseptabelt salt derav
BR9710780A (pt) Novos compostos de para-terefenila
DK633088D0 (da) Hidtil ukendte forbindelser
NO911121D0 (no) Fremgangsmaate for fremstilling av nye skvalen-synetase-inhibitorer.
PE20020524A1 (es) 7-oxo-piridopirimidinas como inhibidores de quinasas
DK173783D0 (da) Fremgangsmade til fremstilling af imidazo (1,2-alfa)pyridiner
DE60001182D1 (de) Erythromycin-Derivate, ihr Verfahren zur Herstellung und ihre Verwendung als Arzneimittel
NZ228065A (en) 1,2,4-triazinediones and parasiticidal compositions; processes for preparation
FI812183L (fi) 3,1-benzoxazin-2-oner deras framstaellning och anvaendning
NO20002490L (no) FremgangsmÕte for fremstilling av 1,4-dihydropyridiner og forbindelser anvendt ved denne fremgangsmÕten
AU561679B2 (en) 5-alkyl-1,6-naphtyridin-2(1h)-ones
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem
EP1216988A4 (en) THIOALKYLAMINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
HUT42277A (en) Herbicides containing as active subtance derivatives of new 1-aryl-4-nitro-pirasole and process for production of the active substances
HUT44012A (en) Herbicide compositions containing new aryl-tetrahydro-phtalimide derivatives and process for producing the active components
BR0010488A (pt) Tienocicloalqu(en)ilamino-1,3,5-triazinas substituìdas
IT1313702B1 (it) Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine.
DK0627429T3 (da) Loracarbefisopropanolat og fremgangsmåde til omdannelse af loracarbefisopropanolat til loracarbefmonohydrat
HUT36469A (en) Process for producing 2-/n-pyrrolidino/-3-isobuthyloxy-n-/substituted phenyl/-n-benzyl-propyl-amines and acid additional salts thereof
DK0786459T3 (da) Fremgangsmåde til fremstilling af en heterobicyklisk alkoholenantiomer
DK1250335T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af imidazopyridiner
DE60335960D1 (de) 1,2,4-triazolderivat, verfahren zu dessenherstellung, und dieses enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application